ArticleJournal for immunotherapy of cancer2022

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.

Akie Kimura Yoshikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.